James Breidenstein

Jim Breidenstein currently serves as the President and Chief Commercial Officer.  Jim became the President in February of 2023.  Before joining PainScript, Mr. Breidenstein previously served as the Global Vice President for PEAR Therapeutics where he stood up commercial operations for the commercialization of the first and only Prescription Digital Therapeutic.  Jim oversaw the creation, launch, and scale of this market creating offering.

Prior to his tenure at PEAR, Jim has been an Executive Leader in the start-up med-device and digital health space for 20 years adding nearly 8 billion dollars in shareholder value.

Jim was a commercial executive at Kyphon Inc, the first minimally invasive spinal surgery company from conception to acquisition.  Mr. Breidenstein introduced the first and only med-device to the world of Psychiatry at Neuronetics.  Jim led and scaled the organization to an ultimate IPO.  Jim then joined Cardiovascular Systems, Inc. where he led the world’s first coronary orbital atherectomy product offering, adding $1.6B in shareholder value.   As a skilled advisor and expert in the field, Jim has been a consultant for many of the leading telehealth and digital health companies.

Jim earned his BA, Business Studies, State University at Buffalo.  Jim also completed the Executive Educational Program, Marketing Healthcare Products, The Kellogg School of Management, Northwestern University.  

Jim, his wife, and four boys live in sunny Buffalo, NY where they enjoy the winters, but you can catch them at “the lake” on the weekends during the summer months.  Go Bills!

‍

‍